19 June 2013
Keywords: galvus, cuts, blood, sugar, type, diabetes, swiss
Article | 02 July 2007
Swiss drug major Novartis has reported data which show that its diabetes treatment Galvus (vildagliptin) brought about consistent and robust
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
2 July 2007
18 June 2013
© 2013 thepharmaletter.com